University Institute of Pharma Sciences (UIPS), Chandigarh University, NH-95 Chandigarh Ludhiana Highway, Mohali, Punjab, India.
Curr Pharm Des. 2024;30(37):2922-2936. doi: 10.2174/0113816128319233240725103706.
Solid Lipid Nanocarriers (SLNs) offer a promising avenue for breast cancer treatment, a disease that accounts for 12.5% of global cancer cases. Despite strides in combined therapies (surgery, chemotherapy, radiation, and endocrine therapy), challenges like systemic toxicity, drug resistance, and adverse effects persist. The manuscript offers several novel contributions to the field of breast cancer treatment through the use of SLNs, and these are innovative drug delivery systems, multifunctionality, and biocompatibility, the potential to overcome drug resistance, integration with emerging therapies, focus on personalized medicine, ongoing and future research directions and potential for reduced side effects. SLNs present a novel strategy due to their unique physicochemical properties. They can encapsulate both hydrophilic and hydrophobic drugs, ensuring controlled release and targeted delivery, thus enhancing solubility and bioavailability and reducing side effects. The multifunctional nature of SLNs improves drug delivery while their biocompatibility supports their potential in cancer therapy. Challenges for pharmacists include maintaining stability, effective drug loading, and timed delivery. Combining SLNs with emerging therapies like gene and immunotherapy holds promise for more effective breast cancer treatments. SLNs represent a significant advancement, providing precise drug delivery and fewer side effects, with the potential for overcoming drug resistance. Ongoing research will refine SLNs for breast cancer therapy, targeting cells with minimal side effects and integrating with other treatments for comprehensive approaches. Advances in nanotechnology and personalized medicine will tailor SLNs to specific breast cancer subtypes, enhancing effectiveness. Clinical trials and new treatment developments are crucial for realizing SLNs' full potential in breast cancer care. In conclusion, SLNs offer a transformative approach to breast cancer treatment, addressing issues of drug delivery and side effects. Ongoing research aims to optimize SLNs for targeted therapy, potentially revolutionizing breast cancer care and providing hope for patients.
固体脂质纳米载体 (SLNs) 为乳腺癌治疗提供了一个有前途的途径，这种疾病占全球癌症病例的 12.5%。尽管在联合治疗（手术、化疗、放疗和内分泌治疗）方面取得了进展，但仍存在系统毒性、耐药性和不良反应等挑战。本文通过使用 SLNs 为乳腺癌治疗领域做出了几项新颖的贡献，这些贡献包括创新的药物传递系统、多功能性和生物相容性、克服耐药性的潜力、与新兴疗法的整合、专注于个性化医学、正在进行和未来的研究方向以及减少副作用的潜力。SLNs 因其独特的物理化学性质而呈现出一种新颖的策略。它们可以封装亲水性和疏水性药物，确保控制释放和靶向递送，从而提高溶解度和生物利用度并减少副作用。SLNs 的多功能性质改善了药物传递，而其生物相容性支持了它们在癌症治疗中的潜力。药剂师面临的挑战包括保持稳定性、有效药物负载和定时递送。将 SLNs 与新兴疗法（如基因和免疫疗法）结合使用，有望为更有效的乳腺癌治疗提供希望。SLNs 代表了重大进展，提供了精确的药物递送和更少的副作用，具有克服耐药性的潜力。正在进行的研究将进一步改进 SLNs 用于乳腺癌治疗，以最小的副作用靶向细胞，并与其他治疗方法相结合，以实现全面的方法。纳米技术和个性化医学的进步将使 SLNs 针对特定的乳腺癌亚型进行定制，提高治疗效果。临床试验和新的治疗方法的发展对于实现 SLNs 在乳腺癌护理中的全部潜力至关重要。总之，SLNs 为乳腺癌治疗提供了一种变革性的方法，解决了药物传递和副作用的问题。正在进行的研究旨在优化 SLNs 用于靶向治疗，有可能彻底改变乳腺癌护理并为患者带来希望。
